Ashermed Secures ￥10 Million in Series A Funding

(VCBeat) Mar. 29, 2021 -- Recently, Ashermed, an innovative clinical CRO service provider based on Internet technology, announced that it has secured tens of millions of yuan in Series A financing, jointly led by Topping Capital and Insight Capital. Index Capital served as the exclusive financial adviser for the latest round. 

The funds are earmarked for the R&D of the intelligent clinical research management system, talent recruitment, market expansion, and the R&D and commercialization of innovative drugs.

Founded in 2013, Ashermed is an innovative CRO specializing in providing clinical research and related technical services to domestic and foreign pharmaceutical enterprises. With the advantages accumulated in technology and excellent reputation in service, Ashermed has achieved the accomplishment of many innovative clinical research projects, and established stable cooperation with many leading medical device companies, which has been recognized by the market.

Ashermed has independently developed a number of clinical research technology platforms, covering research program design, clinical data collection and monitoring, and clinical management, to realize standardized and automated clinical research services online, thus improving efficiency and reducing costs.

In the research design stage, Ashermed utilizes a rich program library to automatically generate customized programs and configure CRF, effectively reducing manpower and time cost by 50%. In the research implementation stage, Ashermed uses smart Internet technology to realize the automatic conversion of data collection and online monitoring, which improves the data management efficiency by 15 times compared with the traditional mode and greatly shortens the research cycle.

Founded in 2012 and based in Shanghai, Topping Capital is a financial institution focusing on equity investment opportunities in strategic emerging industries. The company has invested in a number of projects including four generations of information technology, new energy, new materials, and biomedicine. 

Insight Capital is a venture capital firm focused on early-stage healthcare investment. It mainly invests in medical devices, medical services, new drug research and development, mobile health, and other segments.